Abstract: The RAS family of oncoproteins plays a critical role in driving aggressive malignancies, yet targeting these proteins has historically been challenging due to their "undruggable" nature. While mutation-specific inhibitors have shown clinical efficacy in certain cancers, their utility is limited by narrow mutational applicability and the rapid emergence of resistance. RMC-7977 has emerged as a novel, broad-spectrum pan-RAS(ON) inhibitor that targets the active GTP-bound state of all RAS isoforms (KRAS, HRAS, and NRAS). By forming a tri-complex with cyclophilin A and RAS-GTP, RMC-7977 effectively silences downstream oncogenic signaling. Preclinical studies demonstrate its potent antitumor activity, ability to overcome resistance to allele-specific inhibitors, and capacity to favorably remodel the tumor microenvironment. Notably, recent preclinical evaluations have highlighted the therapeutic potential of RMC-7977 in Acute Myeloid Leukemia (AML) harboring signaling mutations. This review synthesizes the pharmacological activity, molecular mechanisms, limitations, and future perspectives of RMC-7977, with a focus on its application in RAS-driven cancers including AML.
1. Introduction
The RAS family of proto-oncogenes, comprising KRAS, HRAS, and NRAS, encodes small GTPase proteins that function as molecular switches regulating essential cellular processes such as growth, survival, and proliferation [1]. Activating mutations in these genes shift the equilibrium toward a constitutively active, GTP-bound state, driving oncogenic signaling and tumor progression across various aggressive cancers [1]. Historically, RAS proteins were considered "undruggable" due to the lack of suitable binding pockets on their surface. Although recent advancements have led to the approval of mutation-specific inhibitors (e.g., sotorasib and adagrasib for KRAS G12C), these therapies face significant limitations, including restricted applicability to specific mutational profiles and the rapid onset of acquired resistance through secondary mutations or the activation of wild-type RAS isoforms [1].
To overcome these barriers, research has shifted toward the development of broad-spectrum, multi-selective pan-RAS inhibitors. RMC-7977 is a prominent preclinical tool compound in this new class of therapeutics, designed to target the active GTP-bound state of all RAS isoforms simultaneously [1]. While extensively studied in solid tumors like pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), emerging preclinical evidence also underscores the therapeutic promise of RMC-7977 in hematological malignancies, specifically Acute Myeloid Leukemia (AML) with signaling mutations [1]. This review explores the mechanistic advances and therapeutic potential of RMC-7977 in the context of RAS-driven malignancies.
2. Pharmacological Activity
RMC-7977 exhibits robust pharmacological activity by directly targeting the RAS oncoprotein, which enables a more efficient suppression of oncogenic signaling compared to agents that target upstream (e.g., SHP2) or downstream (e.g., MEK1/2, ERK1/2) signaling proteins [1]. In preclinical murine xenograft and cell-line studies, RMC-7977 demonstrated significant tumor growth inhibition and profound pathway suppression, evidenced by decreased levels of phosphorylated ERK (pERK) and phosphorylated AKT (pAKT) [1].
Beyond direct tumor growth inhibition, RMC-7977 actively remodels the tumor microenvironment (TME). Treatment with this agent enhances the infiltration of CD4-positive and CD8-positive T cells and increases the expression of major histocompatibility complex class II (MHC II) molecules on tumor cells, thereby improving antigen presentation [1]. Concurrently, it reduces tumor vascularity and decreases the prevalence of immunosuppressive cells, such as M2-like macrophages and myeloid-derived suppressor cells (MDSCs), alleviating immune cell exclusion [1]. In the specific context of hematological malignancies, RMC-7977 has demonstrated notable preclinical activity and therapeutic combination potential in AML models characterized by RAS signaling mutations, highlighting its broad applicability across both solid and liquid tumors [1].
3. Molecular Mechanism of Action
The molecular mechanism of RMC-7977 distinguishes it fundamentally from earlier mutation-specific covalent inhibitors. While agents like KRAS G12C inhibitors target the inactive, GDP-bound RAS(OFF) state, RMC-7977 is a pan-RAS(ON) inhibitor that specifically binds to the active, GTP-bound state of all RAS isoforms (KRAS, HRAS, and NRAS), encompassing both mutant and wild-type forms [1].
Mechanistically, RMC-7977 functions as a molecular glue that forms a tri-complex with the intracellular chaperone protein cyclophilin A (CypA) and the RAS-GTP target [1]. By recruiting CypA, the inhibitor locks RAS in a conformationally restricted, signaling-incompetent configuration. This stabilization prevents the active RAS(ON) form from engaging with its downstream effectors, including phosphoinositide 3-kinase (PI3K), RAF kinases, and RAL guanine nucleotide dissociation stimulator (RAL-GDS) [1]. Consequently, RMC-7977 effectively neutralizes the oncogenic signal at its source, silencing the downstream MAPK and PI3K/AKT signaling cascades [1].
4. Structure-Activity Relationship (SAR)
The structural design of RMC-7977 is central to its broad-spectrum efficacy. The inhibitor is engineered to occupy the switch II pocket (SII-P) of the RAS protein [1]. By binding to this specific pocket, RMC-7977 facilitates the recruitment of CypA to create a nonproductive ternary complex [1]. This structural interaction is crucial because it stabilizes the RAS-GTP complex and significantly reduces the dynamic flexibility of the switch regions that is normally required for effector binding [1]. Because this mechanism targets a conformational state common to the active forms of KRAS, NRAS, and HRAS, RMC-7977 achieves broad isoform coverage and durable pathway inhibition without relying on the presence of a specific mutant residue (such as the cysteine in G12C mutations) [1].
5. Current Limitations
Despite its promising preclinical profile, the development of RMC-7977 faces several limitations and translational challenges. A primary concern is achieving a safe therapeutic index, given the essential role of wild-type RAS signaling in normal tissue homeostasis [1]. Although preclinical models suggest that tumor-specific drug accumulation and the rapid recovery of normal tissues may mitigate these risks, the long-term effects of broad RAS inhibition on healthy tissues remain incompletely understood [1].
Furthermore, while pan-RAS inhibitors restrict the evolutionary escape routes of tumors compared to allele-specific inhibitors, adaptive resistance can still emerge. Preclinical analyses of tumors that relapsed after initial RMC-7977 treatment revealed compensatory mechanisms, including focal amplification of the MYC oncogene, reactivation of the YAP/TAZ-TEAD transcriptional complex, epithelial-mesenchymal transition (EMT), and hyperactivation of receptor tyrosine kinases (RTKs) via autocrine feedback loops [1]. Additionally, the current lack of validated predictive biomarkers poses a significant challenge for optimal patient selection and response monitoring in future clinical applications [1].
6. Future Perspectives
The future development of RMC-7977 and related pan-RAS inhibitors will heavily rely on rational combination strategies to maximize efficacy and prevent adaptive resistance. In vitro experiments have demonstrated that combining RMC-7977 with the YAP-TEAD interaction inhibitor IAG933 successfully suppresses MYC expression, suggesting that dual targeting of RAS signaling and YAP-TEAD-mediated transcription can improve therapeutic durability [1]. Additionally, because RMC-7977 negates the immune-evasive effects of oncogenic RAS and favorably remodels the TME, combining it with immune checkpoint blockade (e.g., anti-PD-1 therapies) represents a highly promising avenue for achieving synergistic tumor control [1].
For hematological indications such as AML, further translational research is required to fully elucidate the efficacy of RMC-7977 in patients harboring specific RAS signaling mutations. Future efforts must also focus on biomarker development—such as monitoring MHC-II expression or T-cell clonality—to identify patient populations most likely to benefit from this broad-spectrum inhibition [1]. Ultimately, the continued optimization of pan-RAS(ON) inhibitors positions them as potentially transformative agents for a wide array of historically recalcitrant RAS-driven cancers.